Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations.
Clinical Pharmacology & Therapeutics February 1, 2025 Ksenia A Vekhova, Eugenia D Namiot, Jörgen Jonsson et al. 43 citations
Ketamine has a long and very eventful pharmacological history. Its enantiomer, esketamine ((S)-ketamine), was approved by the US Food and Drug Administration (FDA) and EMA for patients with treatment-resistant depression (TRD) in 2019. The number of approved indications for ketamine and esketamine continues to increase, as well as the number of clinical trials. This analysis provides a...
DOI: 10.1002/cpt.3478 (opens in new tab)
Full text (opens in new tab)
Esketamine.
Drug.
Clinical trials.
Research.
+8